Juva Life Highlights Chemical Process Success With Successful Scaling Of Novel Compound JUVA-041 For Preclinical Study And Ultimate Commercialization, The Canadian Business Journal

VANCOUVER, British Columbia, OCTOBER 17, 2022 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life”, “Juva” or “Company”) , is a life sciences company with both pharmaceutical research and development and consumer operations in cannabis production and distribution. is shown. This strategy not only enables the identification of new compositions of matter, but also scalable and affordable composition.

“The novel compound Juva-041 has shown potent anti-inflammatory properties in inflammatory phenotypic assays and is currently being scaled up to support preclinical studies,” said Juva CEO and founder. Doug Chloupek says. “Through Juva’s proprietary platform, we have made significant developments identifying the methods and mechanisms of action behind cannabis’ anecdotal therapeutic potential. These studies are the next step in unlocking the hidden value of the cannabis plant, with many companies scaling up at Juva-like speed. However, we are very pleased that our alternative approach to medicinal chemistry has proven to be our competitive advantage.”

To date, one of the most significant challenges facing companies is scaling up starting materials and creating finished drug products to support FDA-mandated non-clinical studies. This has seriously hampered existing medicines and consumer access. Juva has discovered novel compounds JUVA-019 and JUVA-041 that exhibit superior anti-inflammatory properties compared to many commercial products. This gives Juva significant development and commercial advantages, as learning speed and development costs are significantly reduced over established pharmaceutical approaches.

JUVA-041 is a small molecule isolated from cannabis that was uniquely identified by the Juva Life research team. Like his previously published JUVA-019 (published January 6, 2022), JUVA-041 inhibits key cytokines that have been shown to be clinically relevant to inflammation, but , inhibits with improved selectivity and potency. Through the identification of JUVA-041, we are now demonstrating the efficiency of our discovery approach to discover a second small molecule from cannabis with true anti-inflammatory properties. We believe that the observed clinical effects of cannabis are linked to small molecules with selective anti-inflammatory properties.

Scale-up of JUVA-041 from microgram to 5-gram doses through the standard pharmaceutical stage-gating process allows researchers to continue testing the molecule’s efficacy and toxicity in mouse models. JUVA-041 is a patent pending filed by Juva Life and was identified by Juva chemists through a chemocentric approach to bioactivity identification.

Juva continues its discovery efforts to identify new leads and advance JUVA-041 through industry-standard preclinical inflammation models and non-clinical studies enabling IND filing. Beyond clinical research programs, Juva recently relaunched his WIRB-approved JuLi Registry study, with the goal of cultivating one of the largest datasets on the medical uses of cannabis use to date. .

On behalf of the Board of Directors,

-Doug Klopek-

Doug Klopeck, CEO and Founder

Juba Life Co., Ltd.

[email protected]

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life uses cutting-edge science to discover, develop and commercialize safe and effective health and medicines for both the cannabis consumer segment and the non-cannabinoid-based medical industry. The company is on track to execute his 2018 roadmap, initially by standardizing cultivation, extraction and formulation to deliver reproducible benefits to consumers. Juva has built on these natural product process chemistry skills and now incorporates discovery pharmacology. The Company will leverage the revenues generated from its retail operations to invest in Juva-019 and Juva-041 consumer and clinical development efforts, as well as other potentially valuable pharmaceuticals with significant consumer product and pharmaceutical applications. Promotes non-cannabinoid bioactive substances. Juva is committed to aligning the cannabis market with the next generation of investment grade business models in the space. For more information, see: https://juvalife.com/.

For more information, please contact:

Juba Life Investor Information

phone number: +1 833-333-5882 (Juba)

Email: [email protected]

Investor Relations:
Kyle Porter
858.221.8001
[email protected]

Corporate contact:
1.833.333.JUVA (5882)

forward-looking statements

To the extent that this news release is not historical fact, this news release contains statements and information that may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may include financial and other projections and statements regarding future plans, objectives or economic performance or the assumptions underlying any of the foregoing. In some cases, forward-looking statements are “may,” “would,” “could,” “will,” “likely,” “exclude,” and “expect.” can be identified by terms such as , “believe” and “intend”. , “plans”, “forecasts”, “plans”, “estimates”, “outlooks” or other similar expressions relating to the negative of these or matters that are not historical facts. Examples of such statements include, but are not limited to, statements regarding our purpose and business plans. Product development, commercialization strategies and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and the Company’s actual results, performance or performance may differ materially from future results, performance or performance expressed or implied by forward-looking information. It includes other factors that can cause different. risks associated with our future business plans; The risk that we may not be able to secure key personnel; As with all other risks described in our management’s discussion and analysis under the heading “Risks and Uncertainties” for the year ended December 31, 2020, we The risk of not being able to secure funding on terms or the risk of not being able to raise funding at all. Accordingly, readers should not place undue reliance on such forward-looking information. In addition, forward-looking information speaks only as of the date such statements are made. New factors emerge from time to time and it is not possible for our management to predict all such factors, and we may not be able to predict the impact of each such factor, or factor or combination of factors, on our business. It is impossible to assess in advance how much it will be affected. , actual results may differ materially from those contained in the forward-looking information. We do not use forward-looking information to reflect information or events after the date they were made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. shall not be obliged to update to

CSE does not take responsibility for the adequacy or accuracy of this release.

CBJ Newsmaker